Most biotech stocks have no profit and often no revenue at all, so P/E, P/S and every ratio from the tech guide break. Valuing a biotech comes down to three things a beginner can do with a calculator: count the cash, measure how long it lasts, and price the drug pipeline by its odds of success. This guide walks through each step with a made-up company. The numbers come from any free stock-quote site and the company's latest 10-Q / investor presentation.
Step 0 — Why biotech is different
A biotech company is basically a pile of cash + a few lottery tickets (drugs in trials).
- The cash is real and you can count it.
- Each lottery ticket either becomes a drug worth billions or goes to zero. There's very little in between.
- The company burns cash every quarter running trials. When the cash runs low, it sells new shares (dilution).
So the questions aren't "what's the P/E?" They're:
1. How much is the cash worth vs the stock price?
2. How long until they need more money?
3. What are the drugs worth if they work, times the odds that they work?
4. When is the next event that will tell us?
Step 1 — Classify the company
| Stage | What it means | What drives the stock |
|---|---|---|
| Preclinical / Phase 1 | Drug tested in animals or small safety trials | Pure story + cash. Very high risk |
| Phase 2 | First real test of whether the drug works | Phase 2 data is the biggest make-or-break moment |
| Phase 3 / Filed | Large confirmation trial, or waiting on FDA approval | Odds are much better. Valued on future sales |
| Commercial | Drug approved and selling | Now revenue matters. Start using P/S and the tech-guide tools |
Find the stage in the company's investor presentation (the "pipeline chart" slide) or its 10-K.
Step 2 — Count the cash and work out the "Enterprise Value"
On the stock page: Market Cap, Cash, LT Debt.
Enterprise Value (EV) = Market Cap − Cash + Debt
EV is what the market is paying for the drugs themselves, after you strip out the cash.
Worked example: made-up company "GeneCo"
- Share price $10 × 100M shares = Market cap $1.0B
- Cash $400M, debt $0
- EV = $1.0B − $0.4B = $600M
So the market values GeneCo's whole pipeline at $600M. Remember that number. We compare it with the pipeline value in Step 5.
Special case: EV near zero or negative. If market cap ≤ cash, the market is saying the drugs are worth nothing (or that management will burn the cash). These "trading below cash" names can rocket on any good news. They're also often there for a reason (a failed trial, high burn).
⚠️ The Cash number on the stock page may only include cash + equivalents. Many biotechs also hold "short-term investments" or "marketable securities." Add those in from the 10-Q balance sheet.
Step 3 — Cash runway: the most important number in small biotech
Quarterly burn = how much cash the company loses per quarter.
Easy way: take Op Cash Flow (TTM) from the stock page, which will be negative, and divide it by 4.
Runway (in quarters) = Cash ÷ Quarterly burn
GeneCo: Op Cash Flow TTM = −$200M → burn = $50M/quarter
Runway = $400M ÷ $50M = 8 quarters = 2 years
| Runway | What it means |
|---|---|
| < 12 months | 🚨 An offering is coming soon, almost guaranteed. The 10-Q may even say "substantial doubt about ability to continue as a going concern." Search the filing for that phrase |
| 12–24 months | They'll raise money, probably right after good news |
| 24+ months | Comfortable. Can reach the next data readout without a forced raise |
The #1 biotech trading rule: when a small biotech with short runway spikes on good news, it will very often sell shares into the spike, within days and sometimes the same evening. Check the runway before you chase. Also check whether it already has an ATM (at-the-market) program or a shelf (S-3) filed, because that means it can sell stock at any moment.
Step 4 — Know the odds: how often drugs actually make it
This is where most people get burned. They hear "promising Phase 1 data" and think the drug is going to market. Industry data says otherwise.
From the largest public study (BIO / Informa / QLS, Clinical Development Success Rates 2011–2020, ~12,700 phase transitions):
| Drug is currently in… | Chance it eventually gets FDA approval |
|---|---|
| Phase 1 | ~8% (7.9%) |
| Phase 2 | ~15% |
| Phase 3 | ~52% |
| Filed with FDA (NDA/BLA) | ~91% |
The single hardest step is Phase 2 → Phase 3: only about 29% pass. Odds differ by disease. Oncology is lower (about 5% from Phase 1), while hematology and rare disease are higher. Drugs for rare diseases and drugs with a clear biomarker do noticeably better.
Source: BIO — Clinical Development Success Rates 2011–2020
Dummy rule: a Phase 1 drug is a 1-in-12 shot. Don't pay for it as if it were a sure thing.
Step 5 — Napkin pipeline value (simple "risk-adjusted" value)
Wall Street uses a model called rNPV (risk-adjusted net present value). You can get 80% of the answer with a napkin version.
For each drug:
1. Peak sales: how much it could sell per year at its best. Find it in the investor deck, analyst notes, or by estimating (patients × price per year × share of the market).
2. × Sales multiple (~3×): a common rough rule of thumb for what a drug's peak sales are worth as a business. Treat it as a ballpark, not a law.
3. × Probability of approval from Step 4.
4. × Haircut (~50%) for the years of waiting, the money still to be spent, launch risk, and partner royalties.
GeneCo has one drug in Phase 3, peak sales estimate $1.5B/yr:
- $1.5B × 3 = $4.5B if it works
- × 52% (Phase 3 odds) = $2.3B
- × 50% haircut = ≈ $1.2B risk-adjusted value
Compare with Step 2: the market pays $600M (EV) for a pipeline we roughly value at $1.2B.
→ On this napkin math, GeneCo looks undervalued, if the peak-sales estimate is believable. That "if" is where the real work is.
If the same drug were in Phase 1 (8%): $4.5B × 8% × 50% = $180M, well below the $600M EV. Then the market is already paying for success.
Step 6 — Catalysts: the calendar is the trade
Biotech stocks move in jumps around known dates. Write them down:
- Trial data readouts ("topline data expected Q1"): the biggest moves, ±50–80% in a day is common
- PDUFA date: the FDA's deadline to approve or reject. Usually public
- FDA Advisory Committee (AdCom): an expert panel vote before some approvals. A negative vote often crushes the stock even before the FDA decides
- Medical conferences (ASCO for cancer, ASH for blood diseases, etc.): where detailed data gets presented
- Partnership / buyout: big pharma licensing or acquiring a drug validates it and usually brings cash
Key behaviors to know:
- Run-up then "sell the news." Stocks often rise into a PDUFA date and fall even on approval.
- Binary = size small. A failed trial can take a stock down 60–90% overnight. Position size is your stop.
- Good data + short runway = offering. (Step 3, again.)
Step 7 — Red flags checklist
- 🚩 Runway under 12 months, or "going concern" language in the 10-Q
- 🚩 ATM program or fresh shelf: shares can be dumped into any rally
- 🚩 Reverse split history: often a sign of repeated dilution
- 🚩 Tiny trial, no control group ("open-label, single-arm, 12 patients"): early hype data that often fails to repeat
- 🚩 Changed the goalposts: missed the main goal (the "primary endpoint") and now highlighting a secondary or subgroup result
- 🚩 One-drug company with no partner: everything rides on one ticket
- ✅ Good signs: big-pharma partner, well-known healthcare funds buying in (13F / 13D filings), insider buying, 2+ years of runway, a randomized placebo-controlled trial
Step 8 — The 5-minute biotech checklist (print this)
- Stage? Phase 1 / 2 / 3 / commercial
- EV? Market cap − cash (incl. short-term investments) + debt
- Runway? Cash ÷ (Op Cash Flow TTM ÷ 4). Under 4 quarters = offering risk
- Odds? Phase 1 ~8%, Phase 2 ~15%, Phase 3 ~52%, filed ~91%
- Napkin value? Peak sales × 3 × odds × 50%, compared with EV
- Next catalyst? Date + what result the market expects
- Dilution tools? ATM, shelf, warrants outstanding
How this fits a gap / catalyst trader
When a biotech gaps up 30%+ on news, before chasing:
1. Is it real? Read the press release. Randomized trial that hit its primary endpoint = real. "Encouraging early signals" = weaker.
2. Runway? If it's short, expect an offering, which often prices at a discount and knocks the stock back toward the gap. Waiting for the offering to price and then buying the reclaim is a common pattern.
3. What's left? If the drug just got approved, the big catalyst is over. Now it has to sell. If the data was Phase 2, there's still a Phase 3 to come and more upside if the market believes.
4. EV after the gap vs napkin value: has the jump already priced in success?
Companion article: How to Value a Tech Stock, the right tool once a biotech turns commercial and has real revenue.